Prinomastat
 | |
| Clinical data | |
|---|---|
| Pharmacokinetic data | |
| Half-life | 1-5 hours[1] |
| Identifiers | |
| PubChem | CID 466151 |
| ChemSpider | 409762 |
| UNII |
10T6626FRK  |
| ChEMBL | CHEMBL75094 |
| Chemical data | |
| Formula | C18H21N3O5S2 |
| 423.5 g/mol | |
Prinomastat (AG-3340) is a matrix metalloprotease (MMP) inhibitor with specific selectivity for MMPs 2, 3, 9, 13, and 14. Investigations have been carried out to determine whether the inhibition of these MMPs is able to block tumour metastasis by preventing MMP degradation of the extracellular matrix proteins and angiogenesis. Prinomastat underwent a Phase III trial to investigate its effectiveness against non-small cell lung cancer (nsclc), in combination with gemcitabine chemotherapy. However, it was discovered that Prinomastat did not improve the outcome of chemotherapy in advanced Non-Small-Cell Lung Cancer.[1][2]
References
- ↑ 1.0 1.1 Bissett, D; O'Byrne, KJ; von Pawel, J; Gatzemeier, U; Price, A; Nicolson, M; Mercier, R; Mazabel, E; Penning, C; Zhang, MH; Collier, MA; Shepherd, FA (February 2005). "Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer." (PDF). Journal of Clinical Oncology 23 (4): 842–9. doi:10.1200/JCO.2005.03.170. PMID 15681529.
- ↑ Hande, KR; Collier, M; Paradiso, L; Stuart-Smith, J; Dixon, M; Clendeninn, N; Yeun, G; Alberti, D; Binger, K; Wilding, G (February 2004). "Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor." (PDF). Clinical Cancer Research 10 (3): 909–15. doi:10.1158/1078-0432.CCR-0981-3. PMID 14871966.